CORDIS
EU research results

CORDIS

English EN

ADIPOSE DERIVED STROMAL CELLS FOR OSTEOARTHRITIS

Project information

Grant agreement ID: 241719

Status

Closed project

  • Start date

    1 January 2010

  • End date

    30 June 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 12 083 457

  • EU contribution

    € 9 224 472

Coordinated by:

CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER

France

Objective

Osteoarthritis (OA) is a degenerative joint disease for which no efficient therapy is available. The ADIPOA consortium has previously shown that intraarticular injections of stromal cells prevents OA in two different models, but the mechanisms of this chondroprotective effect remains unknown, and the activation of cartilage derived endogenous stem cells is suspected. The participants have experience on cell therapy, logistic and production facilities for adipose derived stromal cells (ASC) and clinical studies focusing on cartilage repair. They have shown that stromal cells have anti-inflammatory and antiapoptosis effets, prevent cells from senescence and protect endogenous cells from oxidative stress. ASC are well described, and the procedure to expand the ASC in GMP clinical grade by one of us has been approved by regulatory authorities. This has prompted us to propose an original and innovative regenerative medicine approach for OA in a four years programme organised around 6 workpackages : · WP 1 ASC biology, cell processing & optimization for chondral protection · WP 2 In vivo validation of chondroprotective effect of ASC · WP 3 Safety, Security & regulatory issues · WP 4 Clinical trial endogenous ASC injected intraarticular in OA · WP 5 Management and Coordination · WP 6 Training and Education ADIPOA project will then lead to the optimisation and standardisation of production procedures. In vivo validation and optimisation shall lead to a phase 1 clinical trial and the design and initiation of a phase 2 controlled study in OA. The ADIPOA Consortium comprises 10 academic and 2 sme participants and gathers researchers and clinicians with expertise in clinical research, chondrocytes and adipose stem cell biology and regenerative medicine. The Sme participation will ensure the dissemination of the project results. The critical mass achieved by the ADIPOA Consortium should enable clinical applications in OA.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER

Address

Avenue Du Doyen Gaston Giraud 191
34000 Montpellier

France

Activity type

Other

EU Contribution

€ 2 167 455

Administrative Contact

Valérie Handweiler (Ms.)

Participants (11)

NATIONAL UNIVERSITY OF IRELAND GALWAY

Ireland

EU Contribution

€ 477 616

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 548 098

ISTITUTO ORTOPEDICO RIZZOLI

Italy

EU Contribution

€ 769 750

Laboratoires MABIO International

France

EU Contribution

€ 385 700

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 636 320

JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG

Germany

EU Contribution

€ 848 150

MRB Forschungszentrum fur Magnet-Resonanz-Bayern e.V.

Germany

EU Contribution

€ 693 440

ETABLISSEMENT FRANCAIS DU SANG

France

EU Contribution

€ 634 687

PROCORE LTD

Israel

EU Contribution

€ 576 600

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 889 944

VALSTYBINIS MOKSLINIU TYRIMU INSTITUTAS INOVATYVIOS MEDICINOS CENTRAS

Lithuania

EU Contribution

€ 596 712

Project information

Grant agreement ID: 241719

Status

Closed project

  • Start date

    1 January 2010

  • End date

    30 June 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 12 083 457

  • EU contribution

    € 9 224 472

Coordinated by:

CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER

France